Prevention of Post-Polypectomy Colorectal Bleeding by Clips in Patients on Anticoagulants
Launched by HELIOS KLINIKEN SCHWERIN · May 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using small clips during a colon polyp removal can help prevent bleeding in patients who are taking blood-thinning medications afterward. Blood thinners are often necessary for patients with certain health conditions, but they can increase the risk of bleeding after procedures like polypectomy, which is the removal of polyps from the colon. Researchers will compare two groups: one that received the clips to help prevent bleeding and another that did not, to see if the clips make a difference.
To join this study, participants must be adults who have had a colonoscopy with polyp removal and have started taking blood thinners afterward. The trial is currently looking for individuals aged 65 and older, and both men and women can participate. If eligible, participants can expect to provide information from their medical records, as the study is observing past procedures rather than conducting new ones. This research could help improve safety for patients who need blood thinners after having polyps removed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult who has received a colonoscopy with endoscopic colorectal polypectomy
- • patient who has received at least one anticoagulant after polypectomy
- Exclusion Criteria:
- • Endoscopic polypectomy was combined with closure of the mucosal defect by a suturing device or full thickness resection device
About Helios Kliniken Schwerin
Helios Kliniken Schwerin is a leading healthcare institution in Germany, specializing in a comprehensive range of medical services and innovative clinical research. As part of the Helios Health Group, one of the largest private hospital operators in Europe, Helios Kliniken Schwerin is dedicated to advancing medical science through rigorous clinical trials. The institution is committed to enhancing patient care and outcomes by exploring new treatments and therapies in a collaborative environment that prioritizes safety and ethical standards. With a focus on multidisciplinary approaches and state-of-the-art facilities, Helios Kliniken Schwerin plays a pivotal role in contributing to the advancement of medical knowledge and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schwerin, Mecklenburg Vorpommern, Germany
Patients applied
Trial Officials
Daniel Schmitz, Dr.med.
Principal Investigator
Helios Kliniken Schwerin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported